Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 128

1.

Transcriptional Profiling of Age-Associated Gene Expression Changes in Human Circulatory CD1c+ Myeloid Dendritic Cell Subset.

Rahmatpanah F, Agrawal S, Scarfone VM, Kapadia S, Mercola D, Agrawal A.

J Gerontol A Biol Sci Med Sci. 2019 Jan 1;74(1):9-15. doi: 10.1093/gerona/gly106.

2.

Assessing Researcher Needs for a Virtual Biobank.

van Draanen J, Davidson P, Bour-Jordan H, Bowman-Carpio L, Boyle D, Dubinett S, Gardner B, Gardner J, McFall C, Mercola D, Nakazono T, Soares S, Stoppler H, Tempero M, Vandenberg S, Wan YJ, Dry S.

Biopreserv Biobank. 2017 Jun;15(3):203-210. doi: 10.1089/bio.2016.0009. Epub 2016 Dec 8.

3.

When Anti-Aging Studies Meet Cancer Chemoprevention: Can Anti-Aging Agent Kill Two Birds with One Blow?

Yokoyama NN, Denmon A, Uchio EM, Jordan M, Mercola D, Zi X.

Curr Pharmacol Rep. 2015 Dec 1;1(6):420-433. Epub 2015 Apr 14.

4.

Flavokawain A induces deNEDDylation and Skp2 degradation leading to inhibition of tumorigenesis and cancer progression in the TRAMP transgenic mouse model.

Li X, Yokoyama NN, Zhang S, Ding L, Liu HM, Lilly MB, Mercola D, Zi X.

Oncotarget. 2015 Dec 8;6(39):41809-24. doi: 10.18632/oncotarget.6166.

5.

Six stroma-based RNA markers diagnostic for prostate cancer in European-Americans validated at the RNA and protein levels in patients in China.

Zhu J, Pan C, Jiang J, Deng M, Gao H, Men B, McClelland M, Mercola D, Zhong WD, Jia Z.

Oncotarget. 2015 Jun 30;6(18):16757-65.

6.

Correction: Overexpression of periostin in stroma positively associated with aggressive prostate cancer.

Tian Y, Choi CH, Li QK, Rahmatpanah FB, Chen X, Kim SR, Veltri R, Chia D, Zhang Z, Mercola D, Zhang H.

PLoS One. 2015 Jun 4;10(6):e0130333. doi: 10.1371/journal.pone.0130333. eCollection 2015. No abstract available.

7.

Overexpression of periostin in stroma positively associated with aggressive prostate cancer.

Tian Y, Choi CH, Li QK, Rahmatpanah FB, Chen X, Kim SR, Veltri R, Chia D, Zhang Z, Mercola D, Zhang H.

PLoS One. 2015 Mar 17;10(3):e0121502. doi: 10.1371/journal.pone.0121502. eCollection 2015. Erratum in: PLoS One. 2015;10(6):e0130333.

8.

Associations of prostate cancer risk variants with disease aggressiveness: results of the NCI-SPORE Genetics Working Group analysis of 18,343 cases.

Helfand BT, Roehl KA, Cooper PR, McGuire BB, Fitzgerald LM, Cancel-Tassin G, Cornu JN, Bauer S, Van Blarigan EL, Chen X, Duggan D, Ostrander EA, Gwo-Shu M, Zhang ZF, Chang SC, Jeong S, Fontham ET, Smith G, Mohler JL, Berndt SI, McDonnell SK, Kittles R, Rybicki BA, Freedman M, Kantoff PW, Pomerantz M, Breyer JP, Smith JR, Rebbeck TR, Mercola D, Isaacs WB, Wiklund F, Cussenot O, Thibodeau SN, Schaid DJ, Cannon-Albright L, Cooney KA, Chanock SJ, Stanford JL, Chan JM, Witte J, Xu J, Bensen JT, Taylor JA, Catalona WJ.

Hum Genet. 2015 Apr;134(4):439-50. doi: 10.1007/s00439-015-1534-9. Epub 2015 Feb 26.

9.

The identification of trans-associations between prostate cancer GWAS SNPs and RNA expression differences in tumor-adjacent stroma.

Chen X, McClelland M, Jia Z, Rahmatpanah FB, Sawyers A, Trent J, Duggan D, Mercola D.

Oncotarget. 2015 Jan 30;6(3):1865-73.

10.

Early Growth Response 3 regulates genes of inflammation and directly activates IL6 and IL8 expression in prostate cancer.

Baron VT, Pio R, Jia Z, Mercola D.

Br J Cancer. 2015 Feb 17;112(4):755-64. doi: 10.1038/bjc.2014.622. Epub 2015 Jan 29.

11.

A class of genes in the HER2 regulon that is poised for transcription in breast cancer cell lines and expressed in human breast tumors.

Rahmatpanah FB, Jia Z, Chen X, Char JE, Men B, Franke AC, Jones FE, McClelland M, Mercola D.

Oncotarget. 2015 Jan 20;6(2):1286-301.

12.

Wnt signaling in castration-resistant prostate cancer: implications for therapy.

Yokoyama NN, Shao S, Hoang BH, Mercola D, Zi X.

Am J Clin Exp Urol. 2014 Apr 15;2(1):27-44.

13.

Role of the adjacent stroma cells in prostate cancer development and progression: synergy between TGF-β and IGF signaling.

Lee C, Jia Z, Rahmatpanah F, Zhang Q, Zi X, McClelland M, Mercola D.

Biomed Res Int. 2014;2014:502093. doi: 10.1155/2014/502093. Epub 2014 Jun 25. Review.

14.

The transcription factor EGR1 localizes to the nucleolus and is linked to suppression of ribosomal precursor synthesis.

Ponti D, Bellenchi GC, Puca R, Bastianelli D, Maroder M, Ragona G, Roussel P, Thiry M, Mercola D, Calogero A.

PLoS One. 2014 May 1;9(5):e96037. doi: 10.1371/journal.pone.0096037. eCollection 2014.

15.

Generation of "virtual" control groups for single arm prostate cancer adjuvant trials.

Jia Z, Lilly MB, Koziol JA, Chen X, Xia XQ, Wang Y, Skarecky D, Sutton M, Sawyers A, Ruckle H, Carpenter PM, Wang-Rodriguez J, Jiang J, Deng M, Pan C, Zhu JG, McLaren CE, Gurley MJ, Lee C, McClelland M, Ahlering T, Kattan MW, Mercola D.

PLoS One. 2014 Jan 21;9(1):e85010. doi: 10.1371/journal.pone.0085010. eCollection 2014.

16.

A gradient boosting algorithm for survival analysis via direct optimization of concordance index.

Chen Y, Jia Z, Mercola D, Xie X.

Comput Math Methods Med. 2013;2013:873595. doi: 10.1155/2013/873595. Epub 2013 Nov 20.

17.

Expression differences between African American and Caucasian prostate cancer tissue reveals that stroma is the site of aggressive changes.

Kinseth MA, Jia Z, Rahmatpanah F, Sawyers A, Sutton M, Wang-Rodriguez J, Mercola D, McGuire KL.

Int J Cancer. 2014 Jan 1;134(1):81-91. doi: 10.1002/ijc.28326. Epub 2013 Jul 13.

18.

Histone lysine-specific methyltransferases and demethylases in carcinogenesis: new targets for cancer therapy and prevention.

Tian X, Zhang S, Liu HM, Zhang YB, Blair CA, Mercola D, Sassone-Corsi P, Zi X.

Curr Cancer Drug Targets. 2013 Jun;13(5):558-79. Review.

19.

Natural products and transforming growth factor-beta (TGF-β) signaling in cancer development and progression.

Lee C, Zhang Q, Kozlowski J, Brendler C, B Soares M, Dash A, McClelland M, Mercola D.

Curr Cancer Drug Targets. 2013 Jun;13(5):500-5. Review.

20.

Early growth response 3 (Egr3) is highly over-expressed in non-relapsing prostate cancer but not in relapsing prostate cancer.

Pio R, Jia Z, Baron VT, Mercola D; UCI NCI SPECS Consortium of the Strategic Partners for the Evaluation of Cancer Signatures-Prostate Cancer.

PLoS One. 2013;8(1):e54096. doi: 10.1371/journal.pone.0054096. Epub 2013 Jan 14.

21.

Plasma-derived exosomal survivin, a plausible biomarker for early detection of prostate cancer.

Khan S, Jutzy JM, Valenzuela MM, Turay D, Aspe JR, Ashok A, Mirshahidi S, Mercola D, Lilly MB, Wall NR.

PLoS One. 2012;7(10):e46737. doi: 10.1371/journal.pone.0046737. Epub 2012 Oct 16.

22.

An accurate prostate cancer prognosticator using a seven-gene signature plus Gleason score and taking cell type heterogeneity into account.

Chen X, Xu S, McClelland M, Rahmatpanah F, Sawyers A, Jia Z, Mercola D.

PLoS One. 2012;7(9):e45178. doi: 10.1371/journal.pone.0045178. Epub 2012 Sep 28.

23.

A sample selection strategy to boost the statistical power of signature detection in cancer expression profile studies.

Jia Z, Wang Y, Hu Y, McLaren C, Yu Y, Ye K, Xia XQ, Koziol JA, Lernhardt W, McClelland M, Mercola D.

Anticancer Agents Med Chem. 2013 Feb;13(2):203-11.

24.

Expression changes in the stroma of prostate cancer predict subsequent relapse.

Jia Z, Rahmatpanah FB, Chen X, Lernhardt W, Wang Y, Xia XQ, Sawyers A, Sutton M, McClelland M, Mercola D.

PLoS One. 2012;7(8):e41371. doi: 10.1371/journal.pone.0041371. Epub 2012 Aug 1. Erratum in: PLoS One. 2012;7(9). doi: 10.1371/annotation/7de63575-e5c9-4f1d-bb45-fc6420e92c71.

25.

TGF-β mediated DNA methylation in prostate cancer.

Lee C, Zhang Q, Zi X, Dash A, Soares MB, Rahmatpanah F, Jia Z, McClelland M, Mercola D.

Transl Androl Urol. 2012 Jun;1(2):78-88.

26.

Expression of HER2 in Breast Cancer Promotes a Massive Reorganization of Gene Activity and Suggests a Role for Epigenetic Regulation.

Rahmatpanah F, Jia Z, Chen X, Jones FE, McClelland M, Mercola D.

J Data Mining Genomics Proteomics. 2012;3. pii: e102. No abstract available.

27.

Diagnosis of prostate cancer using differentially expressed genes in stroma.

Jia Z, Wang Y, Sawyers A, Yao H, Rahmatpanah F, Xia XQ, Xu Q, Pio R, Turan T, Koziol JA, Goodison S, Carpenter P, Wang-Rodriguez J, Simoneau A, Meyskens F, Sutton M, Lernhardt W, Beach T, Monforte J, McClelland M, Mercola D.

Cancer Res. 2011 Apr 1;71(7):2476-87. doi: 10.1158/0008-5472.CAN-10-2585.

28.

Prostate cancer postoperative nomogram scores and obesity.

Major JM, Klonoff-Cohen HS, Pierce JP, Slymen DJ, Saltzstein SL, Macera CA, Mercola D, Kattan MW.

PLoS One. 2011 Feb 24;6(2):e17382. doi: 10.1371/journal.pone.0017382.

29.

In silico estimates of tissue components in surgical samples based on expression profiling data.

Wang Y, Xia XQ, Jia Z, Sawyers A, Yao H, Wang-Rodriquez J, Mercola D, McClelland M.

Cancer Res. 2010 Aug 15;70(16):6448-55. doi: 10.1158/0008-5472.CAN-10-0021. Epub 2010 Jul 27.

30.

Siah2-dependent concerted activity of HIF and FoxA2 regulates formation of neuroendocrine phenotype and neuroendocrine prostate tumors.

Qi J, Nakayama K, Cardiff RD, Borowsky AD, Kaul K, Williams R, Krajewski S, Mercola D, Carpenter PM, Bowtell D, Ronai ZA.

Cancer Cell. 2010 Jul 13;18(1):23-38. doi: 10.1016/j.ccr.2010.05.024.

31.
32.

WIF1, a Wnt pathway inhibitor, regulates SKP2 and c-myc expression leading to G1 arrest and growth inhibition of human invasive urinary bladder cancer cells.

Tang Y, Simoneau AR, Liao WX, Yi G, Hope C, Liu F, Li S, Xie J, Holcombe RF, Jurnak FA, Mercola D, Hoang BH, Zi X.

Mol Cancer Ther. 2009 Feb;8(2):458-68. doi: 10.1158/1535-7163.MCT-08-0885. Epub 2009 Jan 27.

33.

Timing of consent for the research use of surgically removed tissue: is postoperative consenting acceptable?

Hewitt R, Watson PH, Dhir R, Aamodt R, Thomas G, Mercola D, Grizzle WE, Morente MM.

Cancer. 2009 Jan 1;115(1):4-9. doi: 10.1002/cncr.23999. No abstract available.

34.

PTEN regulation by Akt-EGR1-ARF-PTEN axis.

Yu J, Zhang SS, Saito K, Williams S, Arimura Y, Ma Y, Ke Y, Baron V, Mercola D, Feng GS, Adamson E, Mustelin T.

EMBO J. 2009 Jan 7;28(1):21-33. doi: 10.1038/emboj.2008.238. Epub 2008 Dec 4.

35.

Egr1 regulates the coordinated expression of numerous EGF receptor target genes as identified by ChIP-on-chip.

Arora S, Wang Y, Jia Z, Vardar-Sengul S, Munawar A, Doctor KS, Birrer M, McClelland M, Adamson E, Mercola D.

Genome Biol. 2008;9(11):R166. doi: 10.1186/gb-2008-9-11-r166. Epub 2008 Nov 25.

36.

The wisdom of the commons: ensemble tree classifiers for prostate cancer prognosis.

Koziol JA, Feng AC, Jia Z, Wang Y, Goodison S, McClelland M, Mercola D.

Bioinformatics. 2009 Jan 1;25(1):54-60. doi: 10.1093/bioinformatics/btn354. Epub 2008 Jul 15.

37.

Bcl-B expression in human epithelial and nonepithelial malignancies.

Krajewska M, Kitada S, Winter JN, Variakojis D, Lichtenstein A, Zhai D, Cuddy M, Huang X, Luciano F, Baker CH, Kim H, Shin E, Kennedy S, Olson AH, Badzio A, Jassem J, Meinhold-Heerlein I, Duffy MJ, Schimmer AD, Tsao M, Brown E, Sawyers A, Andreeff M, Mercola D, Krajewski S, Reed JC.

Clin Cancer Res. 2008 May 15;14(10):3011-21. doi: 10.1158/1078-0432.CCR-07-1955.

38.

Claudin-1 immunohistochemistry for distinguishing malignant from benign epithelial lesions of prostate.

Krajewska M, Olson AH, Mercola D, Reed JC, Krajewski S.

Prostate. 2007 Jun 15;67(9):907-10.

PMID:
17440968
39.

A network of p73, p53 and Egr1 is required for efficient apoptosis in tumor cells.

Yu J, Baron V, Mercola D, Mustelin T, Adamson ED.

Cell Death Differ. 2007 Mar;14(3):436-46. Epub 2006 Sep 22. Erratum in: Cell Death Differ. 2007 Mar;14(3):640.

40.

Messenger RNAs under differential translational control in Ki-ras-transformed cells.

Spence J, Duggan BM, Eckhardt C, McClelland M, Mercola D.

Mol Cancer Res. 2006 Jan;4(1):47-60.

41.

"Promoter array" studies identify cohorts of genes directly regulated by methylation, copy number change, or transcription factor binding in human cancer cells.

Wang Y, Hayakawa J, Long F, Yu Q, Cho AH, Rondeau G, Welsh J, Mittal S, De Belle I, Adamson E, McClelland M, Mercola D.

Ann N Y Acad Sci. 2005 Nov;1058:162-85. Review.

PMID:
16394135
42.

Survey of differentially methylated promoters in prostate cancer cell lines.

Wang Y, Yu Q, Cho AH, Rondeau G, Welsh J, Adamson E, Mercola D, McClelland M.

Neoplasia. 2005 Aug;7(8):748-60.

43.

The transcription factor Egr1 is a direct regulator of multiple tumor suppressors including TGFbeta1, PTEN, p53, and fibronectin.

Baron V, Adamson ED, Calogero A, Ragona G, Mercola D.

Cancer Gene Ther. 2006 Feb;13(2):115-24. Review.

44.

Early growth response 1 acts as a tumor suppressor in vivo and in vitro via regulation of p53.

Krones-Herzig A, Mittal S, Yule K, Liang H, English C, Urcis R, Soni T, Adamson ED, Mercola D.

Cancer Res. 2005 Jun 15;65(12):5133-43.

45.

Essential role of p38gamma in K-Ras transformation independent of phosphorylation.

Tang J, Qi X, Mercola D, Han J, Chen G.

J Biol Chem. 2005 Jun 24;280(25):23910-7. Epub 2005 Apr 25.

46.

Identification of promoters bound by c-Jun/ATF2 during rapid large-scale gene activation following genotoxic stress.

Hayakawa J, Mittal S, Wang Y, Korkmaz KS, Adamson E, English C, Ohmichi M, McClelland M, Mercola D.

Mol Cell. 2004 Nov 19;16(4):521-35. Erratum in: Mol Cell. 2005 Jan 7;17(1):161. Omichi, Masahide [corrected to Ohmichi, Masahide].

47.

From mRNA to tumor suppressor.

Mercola D, Welsh J.

Nat Genet. 2004 Sep;36(9):937-8.

PMID:
15340430
48.

Antisense to the early growth response-1 gene (Egr-1) inhibits prostate tumor development in TRAMP mice.

Baron V, Duss S, Rhim J, Mercola D.

Ann N Y Acad Sci. 2003 Dec;1002:197-216.

PMID:
14751836
49.

In silico dissection of cell-type-associated patterns of gene expression in prostate cancer.

Stuart RO, Wachsman W, Berry CC, Wang-Rodriguez J, Wasserman L, Klacansky I, Masys D, Arden K, Goodison S, McClelland M, Wang Y, Sawyers A, Kalcheva I, Tarin D, Mercola D.

Proc Natl Acad Sci U S A. 2004 Jan 13;101(2):615-20.

50.

Inhibition of cell growth by EGR-1 in human primary cultures from malignant glioma.

Calogero A, Lombari V, De Gregorio G, Porcellini A, Ucci S, Arcella A, Caruso R, Gagliardi FM, Gulino A, Lanzetta G, Frati L, Mercola D, Ragona G.

Cancer Cell Int. 2004 Jan 7;4(1):1.

Supplemental Content

Loading ...
Support Center